Please login to the form below

Not currently logged in

FDA gives green light to Merck/MSD’s antibiotic drug Recarbrio

Approved for hospital-acquired/ventilator-associated bacterial pneumonia

Merck HQ

Merck/MSD has won an approval from the US Food and Drug Administration (FDA) for its Gram-negative antibiotic Recarbrio, as a treatment for hospital-acquired and ventilator-associated bacterial pneumonia.

Recarbrio is a combination treatment comprised of imipenem, a carbapenem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor.

Imipenem works to kill the bacteria associated with the infection while the other two active ingredients, cilastatin and relebactam, protect and increase imipenem’s effectiveness.

The new approval in hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) is based on results from the phase 3 RESTORE-IMI 2 trial, which compared Recarbrio to piperacillin/tazobactam (PIP/TAZ). Each drug was administered intravenously every six hours for seven to 14 days, among adult patients with HABP/VABP.

Merck/MSD’s drug met both the primary and secondary endpoints of the trial, demonstrating non-inferiority to (PIP/TAZ) in 28-day all-cause mortality and clinical response at early follow-up.

Recarbrio is also indicated for the treatment of adults who have limited treatment option for complicated urinary tract infections (cUTI) caused by susceptible Gram-negative bacteria.

According to Merck/MSD, Recarbrio should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria, to reduce the development of drug-resistant bacteria and maintain the effectiveness of the drug and other antibacterials.

“At a time of great public health concern about the need for new treatments to meet the evolving challenges posed by Gram-negative bacteria, we are proud to continue bringing new therapeutic options to healthcare practitioners in an effort to help them overcome the challenges in patient care,” said Nicholas Kartsonis, senior vice president, clinical research, infectious diseases and vaccines, Merck Research Laboratories.

Despite antibiotic resistance having been highlighted by the World Health Organisation (WHO) as ‘one of the biggest threats to global health, food security and development today’, few pharma companies are currently researching and developing new antibiotic drugs.

This is due to the fact that the most effective drugs are used last, meaning there is little financial incentive to cover the cost of their development.

Still, there are some players left in the field alongside Merck/MSD, including GlaxoSmithKline which is developing a new antibiotic drug called gepotidacin to treat uncomplicated urinary tract infection (UT) and urogenital gonorrhoea.

Article by

9th June 2020

From: Research, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....
5 ways that lockdowns and restrictions could be affecting our allergies
Over this last year, lockdowns and restrictions have led to changes in the day-to-day environments for people across the world. For Allergy Awareness week, we wanted to explore some of...